临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1353552-97-2

Poseltinib

CAS号:1353552-97-2
分子式: C26H26N6O3 分子量: 470.52
产品形式: Free base
研发状态: Recruiting
研发用途: Relapsed/Refractory Diffuse Large B Cell Lymphoma
研究机构: Seoul National University Hospital
研发日期: May 30 2022
研发阶段: Phase 2
Poseltinib (HM71224, LY3337641) shows a highly selective inhibition for Bruton’s tyrosine kinase (BTK) with IC50 of 1.95 nM, in which the selectivity toward other BMX, TEC and TXK are 0.3, 2.3 and 2.4 fold, respectively.

CAS: 1353550-13-6

Olmutinib (BI 1482694)

中文名称:奥莫替尼
CAS号:1353550-13-6
分子式: C26H26N6O2S 分子量: 486.59
产品形式: free base
研发状态: Completed
研发用途: Healthy
研究机构: Boehringer Ingelheim
研发日期: Apr-16
研发阶段: Phase 1
Olmutinib (BI 1482694) is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase.

CAS: 1352792-74-5

Verinurad (RDEA3170)

中文名称:维立诺雷
CAS号:1352792-74-5
分子式: C20H16N2O2S 分子量: 348.42
产品形式: free base
研发状态: Completed
研发用途: Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
研究机构: AstraZeneca; Parexel
研发日期: March 3 2020
研发阶段: Phase 1
Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter with an IC50 of 25 nM for inhibiting transport activity of human URAT1. It inhibits the related URAT1 homologs OAT4 and OAT1 with approximately 200-fold lower affinity compared to URAT1 with IC50 values of 5.9 µM and 4.6 µM, respectively.

CAS: 1352226-88-0

Ceralasertib (AZD6738)

CAS号:1352226-88-0
分子式: C20H24N6O2S 分子量: 412.51
产品形式: free base
研发状态: Active not recruiting
研发用途: Advanced or Metastatic NSCLC
研究机构: AstraZeneca
研发日期: June 21 2023
研发阶段: Phase 2
Ceralasertib (AZD6738) is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

CAS: 1350653-20-1

Vericiguat

中文名称:维利西呱
CAS号:1350653-20-1
分子式: C19H16F2N8O2 分子量: 426.38
产品形式: Free Base
研发状态: Active not recruiting
研发用途: Chronic Heart Failure With Reduced Ejection Fraction
研究机构: Bayer
研发日期: April 10 2024
研发阶段: --
Vericiguat (BAY1021189, Verquvo) is a potent, orally available and soluble guanylate cyclase (sGC) stimulator.

CAS: 1350636-82-6

Lefamulin acetate (Xenleta)

CAS号:1350636-82-6
分子式: C30H49NO7S 分子量: 567.78
产品形式: Free Base
研发状态: Terminated
研发用途: Mycoplasma Genitalium Infection
研究机构: University of Washington; Nabriva Therapeutics AG
研发日期: April 22 2022
研发阶段: Phase 1 : Phase 2
Lefamulin acetate (Xenleta, BC-3781 acetate) is a pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP) treatment. Lefamulin acetate inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, thus preventing the binding of transfer RNA for peptide transfer.